Evidence map›Paper›PMID 41944382›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

SDS-CRISPR for Single-Nucleotide Variant Detection.

Xin Guan, Chong Guo, Jiongyu Zhang, Rui Yang, Yerramsetti Ramachandra, Chengyu Hou, Minjie Pei, Shuo Zhang, Kurt T Schalper, Xingye Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xin GuanDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Chong GuoDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Jiongyu ZhangDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Rui YangDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Yerramsetti RamachandraDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Chengyu HouDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Minjie PeiDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Shuo ZhangDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Kurt T SchalperDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Xingye LiuDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Qian WuPathology and Laboratory Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA.
Ketan R BulsaraDepartment of Neurosurgery, University of Connecticut Health Center, Farmington, Connecticut, USA.
Changchun LiuDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.ORCID https://orcid.org/0000-0002-4931-986X

Funding

Using human skin grafted mice to identify biomarkers of exposure and study effects of radiation on skinU01AI148306 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2020 to 2024
$2.7M
HIV Viral Load Testing Using CRISPR Cascade Signal AmplificationR01AI194917 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Changchun Liu · 2025 to 2026
$1.3M
NIH HHS R01AI194917NIH HHS U01AI148306UConn Research Excellence Program award
6 · The paper itself

Abstract

The CRISPR-Cas12a system offers a promising platform for simple and sensitive nucleic acid diagnostics, including tumor-associated variant detection and infectious agent identification. However, its intrinsic mismatch tolerance limits its ability to accurately detect single-nucleotide variants (SNVs). Here, we introduce Structure-Disruption-Sensitive CRISPR (SDS-CRISPR), a programmable CRISPR-Cas12a approach that achieves highly precise allele discrimination. Guided by AlphaFold3 modeling and bioinformatic analysis, we uncover how split structural design and ionic modulation reconfigure Cas12a conformations, elucidating the structural basis of SNV discrimination in SDS-CRISPR. We apply SDS-CRISPR to detect IDH1

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsGliomaPolymorphism, Single NucleotideHigh-Throughput Nucleotide SequencingHumansIsocitrate DehydrogenaseMutationIsocitrate DehydrogenaseCRISPR‐based molecular diagnosticsglioma diagnosisIDH1 mutationSDS‐CRISPRsingle‐nucleotide variant detection

Identifiers

PMID41944382
PMCPMC13317634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.